vs
OLD NATIONAL BANCORP（ONB）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是OLD NATIONAL BANCORP的1.1倍（$772.1M vs $702.8M），OLD NATIONAL BANCORP净利率更高（33.3% vs 12.7%，领先20.5%），OLD NATIONAL BANCORP同比增速更快（44.4% vs 5.9%），过去两年OLD NATIONAL BANCORP的营收复合增速更高（34.5% vs 9.0%）
Old National Bank是美国地区性银行，隶属于Old National Bancorp，总部位于芝加哥及印第安纳州埃文斯维尔，总资产485亿美元，拥有250个银行网点、近200家零售分行，是总部设于印第安纳州的最大金融服务银行控股公司，位列全美银行企业前30，业务覆盖美国八个州。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
ONB vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.1倍
$702.8M
营收增速更快
ONB
高出38.5%
5.9%
净利率更高
ONB
高出20.5%
12.7%
两年增速更快
ONB
近两年复合增速
9.0%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $702.8M | $772.1M |
| 净利润 | $233.7M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | — | 14.5% |
| 净利率 | 33.3% | 12.7% |
| 营收同比 | 44.4% | 5.9% |
| 净利润同比 | 61.5% | 3.9% |
| 每股收益（稀释后） | — | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ONBRVTY
| Q1 26 | $702.8M | — | ||
| Q4 25 | $580.8M | $772.1M | ||
| Q3 25 | $574.6M | $698.9M | ||
| Q2 25 | $514.8M | $720.3M | ||
| Q1 25 | $387.6M | $664.8M | ||
| Q4 24 | $394.2M | $729.4M | ||
| Q3 24 | $391.7M | $684.0M | ||
| Q2 24 | $388.4M | $691.7M |
净利润ONBRVTY
| Q1 26 | $233.7M | — | ||
| Q4 25 | $216.6M | $98.4M | ||
| Q3 25 | $182.6M | $46.7M | ||
| Q2 25 | $125.4M | $53.9M | ||
| Q1 25 | $144.7M | $42.2M | ||
| Q4 24 | $153.9M | $94.6M | ||
| Q3 24 | $143.8M | $94.4M | ||
| Q2 24 | $121.2M | $55.4M |
毛利率ONBRVTY
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% |
营业利润率ONBRVTY
| Q1 26 | — | — | ||
| Q4 25 | 46.7% | 14.5% | ||
| Q3 25 | 40.5% | 11.7% | ||
| Q2 25 | 30.2% | 12.6% | ||
| Q1 25 | 46.8% | 10.9% | ||
| Q4 24 | 47.2% | 16.3% | ||
| Q3 24 | 47.2% | 14.3% | ||
| Q2 24 | 40.3% | 12.4% |
净利率ONBRVTY
| Q1 26 | 33.3% | — | ||
| Q4 25 | 37.3% | 12.7% | ||
| Q3 25 | 31.8% | 6.7% | ||
| Q2 25 | 24.4% | 7.5% | ||
| Q1 25 | 37.3% | 6.4% | ||
| Q4 24 | 39.0% | 13.0% | ||
| Q3 24 | 36.7% | 13.8% | ||
| Q2 24 | 31.2% | 8.0% |
每股收益（稀释后）ONBRVTY
| Q1 26 | — | — | ||
| Q4 25 | $0.55 | $0.86 | ||
| Q3 25 | $0.46 | $0.40 | ||
| Q2 25 | $0.34 | $0.46 | ||
| Q1 25 | $0.44 | $0.35 | ||
| Q4 24 | $0.47 | $0.77 | ||
| Q3 24 | $0.44 | $0.77 | ||
| Q2 24 | $0.37 | $0.45 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $8.5B | $7.3B |
| 总资产 | $73.0B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ONBRVTY
| Q1 26 | — | — | ||
| Q4 25 | $1.8B | $919.9M | ||
| Q3 25 | $1.7B | $931.4M | ||
| Q2 25 | $1.8B | $991.8M | ||
| Q1 25 | $1.2B | $1.1B | ||
| Q4 24 | $1.2B | $1.2B | ||
| Q3 24 | $1.2B | $1.2B | ||
| Q2 24 | $1.2B | $2.0B |
股东权益ONBRVTY
| Q1 26 | $8.5B | — | ||
| Q4 25 | $8.5B | $7.3B | ||
| Q3 25 | $8.3B | $7.4B | ||
| Q2 25 | $8.1B | $7.6B | ||
| Q1 25 | $6.5B | $7.6B | ||
| Q4 24 | $6.3B | $7.7B | ||
| Q3 24 | $6.4B | $7.9B | ||
| Q2 24 | $6.1B | $7.9B |
总资产ONBRVTY
| Q1 26 | $73.0B | — | ||
| Q4 25 | $72.2B | $12.2B | ||
| Q3 25 | $71.2B | $12.1B | ||
| Q2 25 | $71.0B | $12.4B | ||
| Q1 25 | $53.9B | $12.4B | ||
| Q4 24 | $53.6B | $12.4B | ||
| Q3 24 | $53.6B | $12.8B | ||
| Q2 24 | $53.1B | $13.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $182.0M |
| 自由现金流经营现金流 - 资本支出 | — | $161.8M |
| 自由现金流率自由现金流/营收 | — | 21.0% |
| 资本支出强度资本支出/营收 | — | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | — | $509.4M |
8季度趋势，按日历期对齐
经营现金流ONBRVTY
| Q1 26 | — | — | ||
| Q4 25 | $159.2M | $182.0M | ||
| Q3 25 | $341.2M | $138.5M | ||
| Q2 25 | $72.9M | $134.3M | ||
| Q1 25 | $108.2M | $128.2M | ||
| Q4 24 | $235.8M | $174.2M | ||
| Q3 24 | $121.3M | $147.9M | ||
| Q2 24 | $161.0M | $158.6M |
自由现金流ONBRVTY
| Q1 26 | — | — | ||
| Q4 25 | $137.3M | $161.8M | ||
| Q3 25 | $333.6M | $120.0M | ||
| Q2 25 | $64.1M | $115.5M | ||
| Q1 25 | $102.4M | $112.2M | ||
| Q4 24 | $229.0M | $149.8M | ||
| Q3 24 | $115.7M | $125.6M | ||
| Q2 24 | $151.6M | $136.6M |
自由现金流率ONBRVTY
| Q1 26 | — | — | ||
| Q4 25 | 23.6% | 21.0% | ||
| Q3 25 | 58.1% | 17.2% | ||
| Q2 25 | 12.4% | 16.0% | ||
| Q1 25 | 26.4% | 16.9% | ||
| Q4 24 | 58.1% | 20.5% | ||
| Q3 24 | 29.5% | 18.4% | ||
| Q2 24 | 39.0% | 19.7% |
资本支出强度ONBRVTY
| Q1 26 | — | — | ||
| Q4 25 | 3.8% | 2.6% | ||
| Q3 25 | 1.3% | 2.6% | ||
| Q2 25 | 1.7% | 2.6% | ||
| Q1 25 | 1.5% | 2.4% | ||
| Q4 24 | 1.7% | 3.4% | ||
| Q3 24 | 1.4% | 3.3% | ||
| Q2 24 | 2.4% | 3.2% |
现金转化率ONBRVTY
| Q1 26 | — | — | ||
| Q4 25 | 0.73× | 1.85× | ||
| Q3 25 | 1.87× | 2.97× | ||
| Q2 25 | 0.58× | 2.49× | ||
| Q1 25 | 0.75× | 3.03× | ||
| Q4 24 | 1.53× | 1.84× | ||
| Q3 24 | 0.84× | 1.57× | ||
| Q2 24 | 1.33× | 2.87× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ONB
暂无分部数据
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
